哌罗匹隆治疗精神分裂症临床疗效及安全性

Clinical efficacy and safety of perospirone in the treatment of schizophrenia

目的探讨哌罗匹隆治疗精神分裂症的临床疗效及安全性。方法将120例精神分裂症患者按照随机数字表法分为研究组与对照组,各60例。研究组给予哌罗匹隆治疗,对照组给予利培酮口崩片治疗,观察8周。采用阳性与阴性症状量表评分减分率判定两组疗效,治疗前、治疗4周及8周末比较两组阳性与阴性症状量表阴性症状子量表评分,比较两组不良反应发生率。结果两组临床疗效比较差异无统计学意义(P>0.05)。治疗4周及8周末两组阳性与阴性症状量表阴性症状子量表评分均显著低于治疗前(P<0.01),研究组显著低于对照组(P<0.05或0.01)。研究组不良反应发生率显著低于对照组(P<0.05)。结论哌罗匹隆治疗精神分裂症患者的总体疗效较好,能显著改善患者的阴性症状,安全性高。

Objective To investigate the clinical efficacy and safety of perospirone in the treatment of schizophrenia.Methods A total of 120 patients with schizophrenia were divided into study group and control group according to random number table method,with 60 cases in each group.The study group was treated with perospirone and the control group was treated with risperidone orally disintegrating tablets for 8 weeks.The positive and negative syndrome scale(PANSS)score reduction rate was used to determine the curative effect of the two groups.The scores of PANSS negative symptom subscale and the incidence of adverse reactions were compared between the two groups before treatment,4 weeks and 8 weeks after treatment.Results There was no statistically significant difference in clinical efficacy between the two groups(P>0.05).At the end of 4 weeks and 8 weeks after treatment,the scores of PANSS negative symptom subscale in the two groups were significantly lower than those before treatment(P<0.01),and the study group was significantly lower than the control group(P<0.05 or 0.01).The incidence of adverse reactions in the study group was significantly lower than that in the control group(P<0.05).Conclusions The overall efficacy of perospirone in the treatment of schizophrenia patients is good,and it can significantly improve the negative symptoms of patients with high safety.